Trial Profile
Safety and efficacy of lenvatinib in radio-iodine refractory advanced differentiated thyroid cancer: A prospective observational multicentric study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology